NCT00293046View on ClinicalTrials.gov

Assessment of Grazax® Treatment Compliance

PHASE3CompletedINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

September 30, 2006

Study Completion Date

October 31, 2007

Conditions
Allergy
Interventions
BIOLOGICAL

ALK Grass tablet - use of compliance device

Trial Locations (1)

1030

Allgergie - Ambulatorium Rennweg, Vienna

All Listed Sponsors
lead

ALK-Abelló A/S

INDUSTRY

NCT00293046 - Assessment of Grazax® Treatment Compliance | Biotech Hunter | Biotech Hunter